Analyst Price Target is $59.44
▲ +47.47% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Xenon Pharmaceuticals in the last 3 months. The average price target is $59.44, with a high forecast of $65.00 and a low forecast of $51.00. The average price target represents a 47.47% upside from the last price of $40.31.
Current Consensus is
Buy
The current consensus among 9 contributing investment analysts is to buy stock in Xenon Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, a Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epileptic encephalopathy; and XEN1101, a Kv7 potassium channel opener, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders. The company's product candidates also comprise NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase II clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. It has a license and collaboration agreement with the Neurocrine Biosciences, Inc. to develop treatments for epilepsy. The company was incorporated in 1996 and is headquartered in Burnaby, Canada.
Read More
